Back to top

Image: Bigstock

Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics

Read MoreHide Full Article

For the quarter ended September 2023, Blueprint Medicines (BPMC - Free Report) reported revenue of $56.57 million, down 14.3% over the same period last year. EPS came in at -$2.20, compared to -$2.23 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $49.58 million, representing a surprise of +14.09%. The company delivered an EPS surprise of +7.95%, with the consensus EPS estimate being -$2.39.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Blueprint Medicines performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Product revenue, net: $54.23 million versus $43.76 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +89.4% change.
  • Revenues- Collaboration and License Revenue: $2.34 million versus the 10-analyst average estimate of $5.65 million. The reported number represents a year-over-year change of -76.3%.
  • Revenues- Product revenue, net- AYVAKIT/AYVAKYT: $54.20 million versus the nine-analyst average estimate of $43.29 million. The reported number represents a year-over-year change of +89.3%.
View all Key Company Metrics for Blueprint Medicines here>>>

Shares of Blueprint Medicines have returned -12% over the past month versus the Zacks S&P 500 composite's -3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

Blueprint Medicines Corporation (BPMC) - free report >>

Published in